Safety and immunogenicity of a randomized phase I prime-boost trial with ALVAC-HIV (vCP205) and gp160 MN/LAI-2 adjuvanted in alum or polyphosphazene

by O'Connell RJ, Polonis VR, Ratto-Kim S, Cox J, Jagodzinski LL, Malia J, Michael NL, Excler J, Robb ML, Kim JH
Published 2012-09-01

Antibody responses to V2 loop are induced by CRF01_A E and not Clade B envelopes

by Karasavvas N, Karnasuta C, Madnote S, Arworn D, Sinangil F, Rerks-Ngarm S, O'Connell RJ, Nitayaphan S, Ngauy V, Kim JH, Michael NL, de Souza MS
Published 2012-09-01